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Summary
Exposure of pregnant women and their unborn children to
engineered nanoparticles (NPs) is not yet of major public
concern. However, this may soon change in light of the
ever-increasing production of NPs and the continuous ap-
pearance of novel NP-containing consumer products.
However, NPs may not only pose risks to exposed indi-
viduals; they offer major potential for the development of
novel therapeutic strategies to treat specifically either the
mother or the developing foetus. Hence there is every reas-
on to explore the transplacental transfer of engineered NPs
in more detail, and to find answers to the vast number of
open questions in this fascinating field of research.
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Should we worry about the new
visitors at the placental door? –
Introduction
For many years, the placenta has been perceived as an im-
penetrable barrier for any pharmacological or toxic agent
between the mother and the foetus, a perfectly secure door
closed to all unknown visitors. But isn’t every door prone
to being opened at some time or another? Indeed, since
the discovery of thalidomide-induced birth defects in the
1960’s, many additional studies have indicated that the pla-
cental door is leakier to many chemical substances and
environmental pollutants than was previously anticipated.
For instance, exposure to alcohol, tobacco, methylmercury,
lead or polychlorinated biphenyls (PCBs) has been shown
to cause deleterious functional, cognitive or reproductive
defects to the foetus [1]. Nevertheless, the placental barrier
is indispensable as it mediates the exchange of nutrients
and metabolic waste products, performs vital metabolic
functions and secretes hormones that maintain pregnancy.
But these days there is a new visitor knocking at the pla-
cental door. With the growing use of nanotechnology, the
placenta is likely to come into contact with novel nano-
particles, either accidentally through exposure to these ma-
terials, or intentionally in the case of potential nanomedical
applications. Should we worry about the new guest, con-
sidering that the placenta is already regularly dealing with
a vast amount of exogenous toxins, particles and chemic-
als? Concerns arise from the exceptional properties associ-
ated with these novel materials. Due to their small size and
high surface area, NPs acquire new physicochemical char-
acteristics not displayed by the corresponding bulk mater-
ials such as catalytic activity, conductivity or mechanical
properties. Although these novel characteristics drive the
development of numerous promising applications in many
fields of technology and medicine, they may also have un-
foreseen effects if particles come into contact with cells and
tissues of the human body. In fact, nanoparticles have a re-
latively marked propensity to cross cell membranes. Biolo-
gical barriers such as the blood-brain barrier that are hardly
amenable to larger particles or drugs can be penetrated
by certain nanomaterials [2]. Therefore it is of major im-
portance to understand whether nanoparticles interfere with
cellular functions and have adverse effects in biological tis-
sues. Apparently these tiny particles comprise a very mixed
crowd of good guys, bad guys and everything in between.
To give a few examples, superparamagnetic iron oxide nan-
oparticles (SPIONs) are in general classified as biocompat-
ible, and some SPIONs are already approved for clinical
application as MRI contrast agents [3]. In contrast, there is
ample evidence to suggest that inhalation of carbon nan-
otubes may provoke pulmonary inflammation, oxidative
stress, and long-term pathological effects such as granulo-
mas, fibrosis and wall thickening [4]. But it is only mar-
ginally understood why some particles are more toxic than
others, as current knowledge of the mechanisms underlying
their adverse effects is very limited. Reverting to the pla-
centa, research on transplacental transfer of nanomaterials
and their effects on the placenta and the growing foetus is
still very much in its infancy. However, studies in this area
should be intensified, not only due to the aforementioned
toxic potential of certain nanoparticles in other organ sys-
tems, but also in the light of epidemiological evidence that
prenatal exposure to environmental fine particles (<2.5 µm
in diameter) and ultrafine particles (<0.1 µm in diameter)
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adversely affects foetal health and development. As such,
increased perinatal mortality, pre-term birth and low birth
weight have been shown to correlate with high particulate
matter exposure during pregnancy [5–8]. In this regard it
is evident now that the growing foetus is particularly vul-
nerable to foreign particles even at doses that do not have
adverse effects in other tissues. Nevertheless, toxicity con-
cerns are only one side of the coin and it is questionable
whether sufficiently large numbers of particles would reach
the placenta in an environmental exposure setting. Anoth-
er, perhaps more relevant motive for strengthening trans-
placental transfer studies is to exploit the potential of nan-
oparticles for novel drug delivery strategies to specifically
target the mother, the placenta or the foetus. Currently, drug
intake during pregnancy is more commonplace than is gen-
erally realised, despite the high concomitant risk of dele-
terious effects on the growing foetus [9, 10]. The fact that
nanoparticles can be tailored to allow efficient drug load-
ing, specific targeting and controlled drug release may help
to lower the requisite therapeutic doses and to prevent off-
target side effects. Moreover, nanoparticle-based therapy
concepts may also help to overcome shortcomings in the
treatment of foetal diseases or placental complications. But
there is still a long way to go before we see whether nano-
particles fulfill our expectations, and we must first acquire
a basic understanding of the behaviour of these particles at
the placental barrier.
What are possible keys to passing
through the placental door? –
Potential uptake mechanisms
Knowing that the placenta is not only permeable to specific
endogenous molecules but also lets pass a number of envir-
onmental substances or drugs, we should now address the
question whether nanoparticles may be taken up by some
of the already known uptake routes. However, before dis-
cussing possible uptake mechanisms, we first examine the
Figure 1
Structure of the placenta barrier in the first trimester and at term.
Illustration of a foetal villus in the first trimester and at term. In early
gestation, the placental barrier separating the foetal (FBS) and
maternal bloodstream (MBS) consists of a syncytium of
syncytiotrophoblasts (ST), a monolayer of cytotrophoblasts (CT)
and the foetal capillary endothelium (E). In between, the basal
lamina (BL) and various cells of the mesenchyme (M) including
fibroblasts (F) and Hofbauer cells (HC) may further restrict the
transfer of NPs across the placenta. At term, the placental barrier is
much thinner due to thinning of the syncytiotrophoblast and the
spreading of the cytotrophoblastic layer. A: foetal artery; FC: foetal
capillary, V: foetal vein.
architecture of the placental door, in particular the cellular
barriers potentially encountered by our small visitors. The
human placenta is of the hemochorial type, in which the
foetal tissue is in direct contact with the maternal blood.
The placental barrier separating maternal and foetal circu-
lation consists of the syncytiotrophoblast, cytotrophoblast
and the foetal capillary endothelium (fig. 1). It decreases
in thickness throughout gestation due to thinning of the
syncytiotrophoblast and spreading of the cytotrophoblastic
layer. Consequently, transfer of substances across the pla-
centa is most efficient in the last trimester when substan-
tial amounts of nutrients are required to sustain rapid foetal
growth.
So far only very few studies have investigated whether
nanoparticles pass the human placenta, and there is virtu-
ally no information on the transplacental uptake mechan-
isms involved. Several mechanisms are already known for
the placental exchange of endogenous substances includ-
ing passive diffusion, facilitated diffusion, active transport,
endocytotic pathways and putative transtrophoblastic chan-
nels [11, 12]. Passive diffusion is the predominant trans-
fer mechanism for most small substances (<500 Da) and
pharmacologically active compounds. It is not energy-de-
pendent and is not saturable. However, passive transfer is
profoundly influenced by the concentration gradient, the
properties of the placenta and the physicochemical charac-
teristics of the substance. If the transport of a compound
down its concentration gradient is mediated by a specific
membrane exchanger protein, it is called facilitated diffu-
sion. This process is passive, saturable and does not require
any input of energy. Only a few exogenous compounds
have been suggested as being transported across the pla-
cental barrier by facilitated diffusion, and chiefly endogen-
ous substances such as glucose, amino acids, nucleosides
and metabolites are exchanged by this transfer route. In
the case of active transport, energy is required to achieve
transport against a concentration gradient. This mechanism
is mediated by particular protein pumps of the syncytio-
trophoblasts, most of which function in the maternal direc-
tion for the excretion of xenobiotics and toxic metabolites.
The ATP-binding cassette (ABC) family of active efflux
pumps comprises the known major placental efflux trans-
porters. However, active transporters are not strictly se-
lective for their substrate and nonphysiological compounds
with structural similarity have the potential to be recog-
nised as well. Whether NPs will cross the placental barri-
er by one of the aforementioned processes is probably de-
pendent on their size, hydrophobicity, polarity and protein
binding, inter alia. However, to our opinion, most NPs will
be too large for passive or facilitated diffusion, particularly
considering their propensity to form small agglomerates in
biological fluids. Nevertheless, we do not completely ex-
clude passive uptake mechanisms for transplacental trans-
fer of NPs, as there is microscopic and mechanistic evid-
ence for such uptake routes for cetain NPs in other cell
types [13]. In addition, NP uptake by active transporters
is also questionable as similarity to other endogenous sub-
stances is unlikely. Rather, different endocytotic pathways
may be involved in the potential transplacental transfer of
certain nanomaterials. Endocytosis is an active process that
is employed by cells for the uptake of large, polar molec-
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ules that cannot pass through the hydrophobic membrane
of a cell. It comprises clathrin-mediated endocytosis, cave-
olae, macropinocytosis and phagocytosis. In all cases, mo-
lecules either absorb to cell membranes or bind to specif-
ic receptors (receptor-mediated endocytosis), followed by
the invagination of cell membranes and formation of intra-
cellular vesicles. Expected size restriction for the uptake is
120 nm for clathrin-medicated endocytosis, 60 nm for ca-
veolae and up to 1 µm for macropinocytosis respectively
[14]. Indeed, syncytial membranes express caveolin-1 [15]
and are richly endowed with clathrin [16, 17]. Once inter-
nalised, endocytotic vesicles can fuse with lysosomes, re-
cycle to the site of entry or translocate to the opposite po-
lar membrane to release their content. Our assumption of
an endocytotic uptake mechanism for larger NPs or small
NP agglomerates at the placental barrier is based on the fact
that endocytotic vesicles exhibit an appropriate size range
and that in many cell types and tissues such NPs often pre-
vail in membrane-bound vesicles in the cytoplasm, indic-
ating an active uptake process [18]. Interestingly, NPs may
even be actively directed towards receptor-mediated endo-
cytotic uptake by functionalising their surface with selected
ligands [19, 20]. In the placenta, receptor-mediated uptake
is, inter alia, employed by immune globulins (IgG) that
bind to Fc receptors on the apical membrane of the syn-
cytiotrophoblast. NPs coated with IgG have already been
used in other circumstances, such as for nanomedical ap-
plications, and it would be interesting to know whether
such functionalised particles have the potential to cross the
placenta in a similar endocytotic process as is described for
the endogenous IgG molecules. Finally, transtrophoblastic
channels of some 20 nm diameter, spanning from maternal
blood across the placental barrier to the fetal blood stream,
have been proposed as an exchange route for small mo-
lecules between the mother and foetus [21–23]. However,
their existence is still very much under discussion and there
is no broad acceptance that these channels are contigu-
ous and functional in intact placentas. Only under elev-
ated foetal hydrostatic pressure was transport of water and
small water-soluble molecules observed, and – notably –
exclusively from the foetal-to-maternal direction [21, 24,
25]. Strong evidence against a contiguous transtrophoblast-
ic channel system in normal placenta is also provided by
the lack of transfer of numerous small water-soluble mo-
lecules, considering that a 20 nm wide pore would easily
accommodate molecules of up to 50,000 Da. In conclusion,
we propose that if Mr. Small and Little Miss Tiny are able
to cross the placental door, they will most likely use one of
the various endocytotic pathways described for endogen-
ous small molecules. But we should also be prepared for
the eventuality that they could just as well manage to find
another, as yet unknown entry route.
Which spyholes are available to
observe the entrance? – Model
systems to study transplacental
transfer
It is evident that translocation studies cannot be performed
in the most perfect model system, namely in pregnant wo-
men, for obvious ethical reasons. Consequently, various al-
ternative models have been developed including human in
vitro and ex vivo systems as well as in vivo transfer stud-
ies in rodents. Here we present a brief overview of some of
the most common model systems to address the transfer of
substances across the placenta (for a comprehensive review
see [26, 27]).
In vitro models using human cell cultures (primary cyto-
trophoblasts or choriocarcinoma cell lines), or isolated
plasma membrane vesicles from human/animal placenta,
are widely used to study transplacental transfer of a variety
of drugs and compounds. The most popular example are
BeWo monolayer cells, a choriocarcinoma derived pla-
cental cell line that strongly resembles cytotrophoblastic
cells. The b30 subclone can be grown on permeable mem-
branes in bicameral chambers to form confluent cell layers,
enabling rates to be determined of both uptake into the
cells from the apical surface and efflux from the basolateral
membrane. BeWo cell monolayers were recently used to
identify peptide ligands that facilitate placental transcytosis
of viral particles across this cell culture model of the human
trophoblast barrier [28]. Although in vitro models allow for
the investigation of specific mechanisms of transfer, such
as the type of transport (active transport, passive diffusion,
transporter proteins or enzymes) they lack anatomical in-
tegrity and blood flow. Thus it remains to be demonstrated
in future whether these in vitro models will be suitable to
address the transfer of NPs across the placenta.
First indications that nanosized materials may cross the
placental tissue did not come from such in vitro models but
were obtained from a study in pregnant rats showing that
gold NPs were transferred to the embryos 24 hours after
Figure 2
Key components of a placental perfusion experimental setup.
The middle picture shows a perfusion system with a perfusion
chamber in a 37% water bath (white square). Other relevant
components include a) gas mixture used for equilibration of the
maternal and foetal circulation (maternal: 95% air, 5% CO2; foetal:
95% N2, 5% CO2); b) peristaltic pump allowing a specific
adjustment of the flow rate; c) oxygenator with a bubble trap;
d) online monitoring of pressure and temperature in the foetal
circulation; e) foetal and maternal reservoir in water bath (37 °C);
f) maternal side of a clamped placenta showing a perfused
cotyledon with three blunt-tipped needles; g) foetal side of a
clamped placenta with cannulated vessels; h) pressure and
temperature sensor in a heating chamber; i) flow meter.
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intravenous injection [29]. However, in rats or mice three
trophoblast layers are present between maternal blood and
fetal blood capillary, whereas in humans a single syncytio-
trophoblast layer arises from the fusion of cytotrophoblast
cells and forms a true syncytium with no lateral cell mem-
branes [30]. Hence, animal data cannot simply be extrapol-
ated to humans because the placenta is the most species-
specific mammalian organ [31]. As a consequence, various
human model systems have been developed trying to mim-
ic the situation in pregnant women as closely as possible in
order to circumvent species-dependent differences. In vivo
studies evaluating the transplacental kinetics of xenobiot-
ics in humans include sampling of umbilical cord blood as
well as of maternal blood at the time of delivery. Calcula-
tion of the cord blood (C) to maternal blood (M) concen-
tration ratio (C:M) can provide information on how much
of a substance did cross the placenta in vivo. However, it
is difficult to determine accurately the transplacental trans-
fer kinetics of a particular substance by this method, be-
cause measurements are taken at only one time point and
typically in a small number of mother–infant pairs. This
is problematic, as there is often wide variability between
pairs due to sample contamination, timing of sample col-
lection, sampling site, interindividual differences, and dur-
ation of exposure. Moreover, maternal venous blood con-
centrations do not reflect those presented to the placenta
and may depend on the tissues drained by the selected vein
if an arteriovenous gradient exists [32]. Yet, sampling of
cord blood is probably only a useful approach to study of
the passage of drugs that are anyway administered during
pregnancy to treat the mother or the foetus but not for NPs
with unknown toxicity. Hence the human placenta perfu-
sion model provides a better surrogate for study of trans-
placental transport of NPs [33–35]. Essentially, the foet-
al artery and vein of an intact cotyledon are cannulated
and the placental tissue is placed in a perfusion chamber
(fig. 2). The maternal side is perfused by introducing three
blunt metal cannulas into the intervillous space by penetra-
tion of the decidual plate. Furthermore, a venous drain con-
nected to a peristaltic pump removes the perfusate from the
chamber and returns it to the maternal reservoir. Foetal and
maternal cannulas are connected to two separate perfusion
circuits, and peristaltic pumps hold the foetal circuit flow
at a rate of 6 mL/min and the maternal circuit at 12 mL/
min. Human placental perfusion models provide informa-
tion on inter alia transplacental transfer, placental metabol-
ism, acute toxicity, the potential role of transporters and
foetal exposure. Although this approach is very close to
the in vivo situation, a major limitation concerns the use of
a full-term placenta that does not allow estimation of the
transfer in the first trimester when the foetus is most vul-
nerable. In principle, first term placentae can be obtained
from elective surgical terminations of pregnancy, but these
tissues are very fragile and difficult to perfuse. Moreover,
it is unclear whether perfusions of such placental tissues
represent the early exposure of healthy pregnant women,
as termination of pregnancy is often due to a pathologic-
al situation (e.g. insufficient placental function). Another
constraint is that the perfusion time is limited to approxim-
ately 4–8 hours, which is sufficient to study bidirectional
transport and short-term effects but is too short to investig-
ate chronic effects. Nevertheless, it has recently been con-
firmed that placental perfusion is a valid model to predict
placental drug transfer at term reliably when adjusting for
extra parameters [32].
Do we already know something about
the new guests? – Current studies on
placental permeability to ENPs
In the past few years, studies on the effects of environ-
mental and engineered nanomaterials in animals or human
placenta model systems have started to emerge (table 1).
For an overview on current understanding of the conse-
quences of prenatal NP exposure for the placenta and foetal
integrity we suggest a review of Menezes et al. as well as
two very recent original articles of Yamashita et al. and Pi-
etroiusti et al. that have not yet been covered by any re-
view [11, 36, 37]. Focusing on the transplacental trans-
fer, it appears that most nanoparticles tested so far were
detected in the foetal circulation or tissues. This strongly
suggests that the placenta does not provide a tight barrier
for nanoparticle entry to the foetus similar to what has
already been discovered for other xenobiotics or drugs.
In rodents, transplacental passage has been reported for
Quantum dots (Qdots) [38], TiO2 NPs [37, 39], SiO2 NPs
[37], C60 fullerenes [40], polystyrene beads (PS) [41] and
gold NPs [42]. Among these nanoparticles, only PS beads
and gold NPs have been studied in a human placenta per-
fusion model system [43, 44]. While PS beads were able
to cross the human placenta in a size-dependent manner
[44], gold NPs were retained in the placenta’s trophoblastic
cell layer [43]. An explanation why gold NPs apparently
pass the rodent but not the human placenta might be the
use of different gold NPs, the different experimental setup
or, more probably, the fairly dissimilar structure of human
and rodent placenta. Or it might simply be a technical issue
as only trace amounts of gold NPs (0.0006% of 1.4 nm
gold NPs and 0.00005% of 18 nm gold NPs) were meas-
ured in foetal mouse tissue [42] and the detection limit of
the method used in the human placenta model was estim-
ated at 0.13–0.2% of particles [43]. In our opinion, reli-
able detection of NPs in the foetal tissues or circulation
and their quantification is in general one of the main chal-
lenges in transplacental transfer studies, especially under
realistic exposure scenarios where transfer rates are expec-
ted to be very low. Besides the lack of sensitivity, detec-
tion often relies on radioactive or fluorescent labelling of
NPs bearing the risk of an unspecific release of the label.
Indeed, there are several studies where the placental pas-
sage of NPs is unclear either because the detection systems
used lacked sensitivity [36, 45] or because no method ex-
isted at all to identify the particles unambiguously (C60
fullerenes in [36], DE in [46, 47]). Nevertheless, from the
few studies that allowed NP tracking, it appears that trans-
placental transfer is not solely dependent on the size of
particles [42, 44] but also on their physicochemical char-
acteristics and coating [38]. Thus our advice to Mr. Little:
if you want to enter make sure you are wearing the right
coat.
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What else do we have to know to
prepare for their visit? – Open
questions remaining
Along the previous lines, the reader may already have
come up with some questions regarding the placental pas-
sage of NPs. Here we will add some of our own reflections
that may likewise help to stimulate future research in this
exciting field.
– Is the ability to cross the placental barrier an inherent
property of all NPs? So far, it appeared that basically
all types of NPs tested were capable of crossing the
placental barrier even if simply in trace amounts. But
as the number of studies on transplacental transfer is
so small, more types of nanomaterials need to be
tested, in particular those with a high exposure risk or
of potential medical use. If NPs pass the human
placenta, it will be of major importance to know more
about the degree of NP-passage as well as the transfer
rates, as the particle dose often determines the
biological effects. In this regard the available
knowledge is scanty, indicating that the percentage of
particles in foetal tissues may be anywhere between
trace amounts as measured for gold NPs (<1%) [42,
48] or significant doses in the case of 80 and 50 nm PS
beads (30–35%) [44]. However, these numbers must
be interpreted with care, taking into consideration the
differences in the routes of administration and the
methods used to quantify the particles. For future
studies it will also be important to take into account
Table 1: Summary of studies on NP transfer across the placenta.
NP type NP size (nm) /
modification
Dose / route of
administration
NP application /
length of exposure
Model
system
Major outcomes Reference
Gold 5 and 30 / radiolabeled 0.02 mg / iv GD 19 / 24 h Rat Transplacental transfer rates of 0.018% for
5 nm and 0.005% for 30 nm NP
[47]
Gold 1.4 and 18 / radiolabeled
and TPPTS
N.s. / iv 3rd trimester / 24 h Rat Size-dependent uptake in placenta (0.03%
of 1.4 nm and 0.0002% of 18 nm NP) and
fetus (0.006% of 1.4 nm and 0.00005% of
18 nm NP)
[41]
Gold 10 / PEG
15 / PEG
10 and 15 / PEG
9.1*109 NP / ml
9.1*109 NP / ml
3.6*1010 NP / ml
6 h perfusion
6, 24 and 48 h in vitro
BeWo
Human No NP transfer observed, particles
accumulate in the trophoblastic cell layer
Uptake and retention of NP in BeWo cells
[42]
TiO2 25-70 0.1 mg / sc GD 3, 7,10 and 14 / P4
and 6 weeks
Mouse NP cross the placenta and can damage the
genital and cranial nervous system
[38]
TiO2 21 / modified with Al, Si
and Zr and coated with
polyalcohols
40 mg/m3; 1h / day / inhalation GD 8-18 / P2 and
P23-24
Mouse Offspring displays neurobehavioral
alterations but unclear if effect is direct or
indirect; transplacental transfer of NPs not
investigated
[44]
TiO2 and
SiO2 (nSP)
35
70, 300 and 1000 / nSP70
carboxylic or amine
0.8 mg (nSP70 also at 0.4 mg) /
iv
GD 16 and 17 / GD 18 Mouse TiO2 and 70 nm SiO2 cause pregnancy
complications but not larger sNPs or
modified sNPs; TiO2 and 70 nm SiO2 are
present in the placenta, fetal liver and fetal
brain
[36]
Silicon
nanovectors
519, 834 and 1000 1.2*109 NP/ml/ iv GD 20 / 4 h Rat Transplacental transfer of the particles is
size dependent (particles > 800 nm do not
cross)
[48]
Polystyrene
beads (PS)
20, 100, 500/ fluorescent,
carboxylic;
200 /fluorescent, amine
from 0.5%w stock: 0.6 µl (PS
20, 100), 8 µl (PS 500), 1.25 µl
(PS 200) /
injection via extraembryonic
tissue
GD 7.5 / 12 h Rat Modification affects transplacental transfer:
Amine-PS 200 pass extraembryonic tissue
while carboxy-PS bigger than 100 nm
accumulate in the extraembryonic tissue
[40]
Polystyrene
beads (PS)
50, 80, 240, 500 /
fluorescent
25 µg/ml 6h perfusion Human Size-dependent transplacental transfer (35%
of PS 50, 30% of PS 80, 9% of PS 240 and
1% of PS 500)
[43]
Quantum-
dots
1.7, 2.6 and 3.2 / pristine
or coated with MPA, PEG
and SiO2
20, 50, 86, 125 µg / iv GD 20-22 / P0 Mouse Size-dependent transfer of particles across
the placenta; coating of particles reduced the
transfer
[37]
Fullerenes Average size < 10 0.3 mg/kg / iv GD 15 / 24 and 48 h Rat Particles cross the placenta and are
transmitted to the offspring
[39]
Single-walled
carbon
nanotubes
850 x 2.37 / pristine; 760 x
1.58 / oxidized;
370 x 1.8 / ultra-oxidized
10 ng to 30 µg / injection into
retrobulbar plexus
0.1-100 µg/ml
GD 5.5 / 10 d
EST (NIH3T3 and mES)
/ 10 d
Mouse Low doses of particles affect embryonic
development; effects more pronounced for
oxidized particles EST predict in vivo data,
identifying oxidized particles as the more
toxic compound
[35]
CoCr 29.5 0.12 mg / iv
0.04 mg/ml
GD 9.5 or 12.5 / 7 d
In vitro transwell co-
cultures (BeWo +
fibroblasts)/ 24 h
Mouse
Human
DNA damage of CoCr NPs across bilayered
but not monolayered barriers
Indirect DNA damage to fibroblasts without
passage of NPs is dependent on thickness
of the BeWo barrier
[49]
[51]
EST: embryonic stem cell test; mES: mouse embryonic stem cells; GD: gestation day; iv: intravenous; MPA: 3-mercaptopropionic acid; NP: nanoparticles; N.s.: not stated;
P: postnatal day; PEG: polyethylene glycol; sc: subcutaneous; TPPTS: sulfonated triphenylphosphine
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the testing of realistic doses to obtain meaningful
results. These values may be rather low for
environmental exposure scenarios, but high for
nanoparticles with medical applications.
– What are the key characteristics of NPs that determine
their transplacental transfer? Particle size appears to be
an important factor as several studies have shown that
the transfer efficiency is higher the smaller the
particles are [38, 42, 44, 49]. In addition, particle
coating appears to play another significant role in their
uptake [37, 38].
– Are adverse effects on embryonic development induced
directly by translocated particles, or are they an
indirect consequence of altered placental permeability
or functionality – or even due to the release of
mediators in the maternal tissue? Indirect effects have
already been proposed by several groups, but clear
evidence is not yet available [36, 37]. Nevertheless, a
small series of articles demonstrating indirect toxicity
of NPs across various in vitro biological barriers seems
to further corroborate this hypothesis [50–52].
Interestingly, indirect toxicity was only observed in
multilayered barriers (including a late gestation BeWo
placenta model) but not in monolayered barriers
(including an early gestation BeWo placenta model)
[52].
– What are the effects of prenatal NP exposure on the
unborn child? Due to ethical reasons, data on the
embryotoxicity of NPs have been obtained from
experiments on pregnant rodents. These studies have
demonstrated that prenatal exposure to carbon
nanotubes, PS beads or small TiO2 NPs correlates with
foetal complications [36, 37, 39, 41]. A feature of note
is that the validated mouse embryonic stem cell test
(EST) was able to predict in vivo toxicity, suggesting
that it can be used to replace in vivo testing in mice
[36].
Finding answers to all of these questions will be a fas-
cinating challenge. Currently available model systems and
biological tests may have to be adapted for the testing of
nanomaterials, as it is well known that NPs have many
ways of interfering with various test procedures. In addi-
tion, entirely new placenta models and detection systems
may need to be developed, requiring a multidisciplinary ef-
fort including experts from the material, chemical, med-
ical and biological fields. As such, it would be of great
interest to devise a novel advanced in vitro model of the
human placenta for high-throughput testing of many dif-
ferent conditions. This would not only allow the rapid pre-
screening of a large variety of nanomaterials, but would
also enable more systematic studies on the uptake or tox-
icity mechanisms. In this direction, simple models such as
a monolayer of BeWo cytotrophoblast cells in a 2D-cul-
ture dish or transwell insert are already described, but they
may not reflect the in vivo situation very closely. A nov-
el approach may comprise the use of primary cells dir-
ectly isolated from placental tissue in combination with a
more in vivo-like setup such as a 3D-placental microtis-
sue or a perfused transwell system. To study the transfer of
nanoparticles primary cytotrophoblasts that spontaneously
form a syncytium without lateral separations may be better
suited to representing the placenta than BeWo cells that are
very difficult to differentiate. Moreover, as translocation of
nanoparticles occurs in a dynamic surrounding, we assume
that a perfused transwell approach or a microfluidic sys-
tem will provide a significantly improved model as com-
pared to a static transwell system. To obtain such a perfused
transwell model, co-cultures of placental cells could be ob-
tained on a transwell insert under static conditions simil-
ar to other multi-type cell models, such as an efficiently
working triple-cell culture system of the lung [53, 54]. To
test nanoparticle translocation, these inserts could then be
placed in a perfusion chamber that allows mimicking of the
maternal and foetal circulation. For mechanistic studies,
3D-microtissues of primary co-cultures or mixed primary
cells and cell lines may provide a good in vivo-like model
system suited to high-throughput testing. Such organotypic
3D microtissue spheres with tissue-like structure and func-
tions can be obtained by gravity-enforced self-assembly of
cells in hanging drops [55]. Ultimately it will be of major
importance to show that such models do indeed represent
an improvement on current in vitro tests, how well they are
suited to the study of nanoparticles and to what extent they
correlate with the ex vivo perfusion system.
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Figures (large format)
Figure 1
Structure of the placenta barrier in the first trimester and at term.
Illustration of a foetal villus in the first trimester and at term. In early gestation, the placental barrier separating the foetal (FBS) and maternal
bloodstream (MBS) consists of a syncytium of syncytiotrophoblasts (ST), a monolayer of cytotrophoblasts (CT) and the foetal capillary
endothelium (E). In between, the basal lamina (BL) and various cells of the mesenchyme (M) including fibroblasts (F) and Hofbauer cells (HC)
may further restrict the transfer of NPs across the placenta. At term, the placental barrier is much thinner due to thinning of the
syncytiotrophoblast and the spreading of the cytotrophoblastic layer. A: foetal artery; FC: foetal capillary, V: foetal vein.
Review article: Current opinion Swiss Med Wkly. 2012;142:w13559
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 8 of 9
Figure 2
Key components of a placental perfusion experimental setup.
The middle picture shows a perfusion system with a perfusion chamber in a 37% water bath (white square). Other relevant components include
a) gas mixture used for equilibration of the maternal and foetal circulation (maternal: 95% air, 5% CO2; foetal: 95% N2, 5% CO2); b) peristaltic
pump allowing a specific adjustment of the flow rate; c) oxygenator with a bubble trap; d) online monitoring of pressure and temperature in the
foetal circulation; e) foetal and maternal reservoir in water bath (37 °C); f) maternal side of a clamped placenta showing a perfused cotyledon
with three blunt-tipped needles; g) foetal side of a clamped placenta with cannulated vessels; h) pressure and temperature sensor in a heating
chamber; i) flow meter.
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